Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
ConclusionsReal-world treatment of 1602 Japanese patients with afatinib was associated with a predictable ADR profile. Afatinib showed effectiveness in inoperable/recurrentEGFR mutation-positive NSCLC, especially as first-line treatment. As with other EGFR TKIs, prompt management of adverse events is needed in the Japanese population, to reduce serious events and outcomes, including interstitial lung disease.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Acne | Cancer | Cancer & Oncology | Drugs & Pharmacology | General Practices | Interstitial Lung Disease | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Primary Care | Study